The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant

Medicine and Dentistry

• Hepatitis B Virus 100%
• Mutant 100%
• Patient 36%
• Cells 27%
• Promoter Region 27%
• Antiviral Therapy 27%
• Lamivudine 18%
• Hepatocellular Carcinoma 18%
• Oncogene C Fos 18%
• Membrane Antigen 18%
• Polymerase 18%
• Adefovir 18%
• Transactivation 18%
• Oncogene C Myc 18%
• SV40 18%
• Gene 9%
• Serum 9%
• Evaluation Study 9%
• Carcinogenicity 9%
• Secretion (Process) 9%
• Sequence Analysis 9%
• Drug Resistance 9%
• Hepatitis B(e) Antigen 9%
• Site-Directed Mutagenesis 9%
• Nucleotide Sequence 9%
• Stop Codon 9%

Immunology and Microbiology

• Surface Property 100%
• Mutant 100%
• Hepatitis B Virus 100%
• Cells 27%
• Promoter Region 27%
• Transactivation 27%
• Experiment 18%
• Oncogene C Myc 18%
• Membrane Antigen 18%
• Nude Mouse 18%
• Oncogene C Fos 18%
• Simian Virus 40 18%
• Gene 9%
• Sample 9%
• Sequence Analysis 9%
• Secretion (Process) 9%
• Drug Resistance 9%
• Nucleotide Sequence 9%
• Site Directed Mutagenesis 9%
• Hepatitis B(e) Antigen 9%
• Stop Codon 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Hepatitis B Virus 100%
• Nude Mouse 40%
• Liver Cell Carcinoma 40%
• Lamivudine 40%
• Membrane Antigen 40%
• Adefovir 40%
• Antiviral Therapy 40%
• Simian Virus 40 40%
• Antivirus Agent 20%
• Drug Resistance 20%
• Carcinogenicity 20%
• Site-Directed Mutagenesis 20%
• Hepatitis B(e) Antigen 20%